user

Preclinical safety of Baxter's recombinant ADAMTS13

被引：0
|
作者：
Piskernik, C. [1 ]
Dietrich, B. [1 ]
Horling, F. [1 ]
Kubik, S. [1 ]
Ruthsatz, T. [1 ]
Scheiflinger, F. [1 ]
Schwarz, H. P. [1 ]
Muchitsch, E. M. [1 ]
Schiviz, A. [1 ]
机构：
[1] Baxter Innovat GmbH, Vienna, Austria
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：789 / 790
页数：2
相关论文
共 50 条
  • [1] Preclinical Safety of Baxter's Recombinant ADAMTS13
    Piskernik, Christina
    Dietrich, Barbara
    Kubik, Susan
    Ruthsatz, Tanja
    Scheiflinger, Friedrich
    Schwarz, Hans Peter
    Muchitsch, Eva-Maria
    [J]. BLOOD, 2012, 120 (21)
  • [2] Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP
    Schiviz, Alexandra
    Resch, Marlene
    Farnleitner, Elisa
    Rottensteiner, Hanspeter
    Scheiflinger, Friedrich
    Schwarz, Hans Peter
    Hoellriegl, Werner
    Muchitsch, Eva-Maria
    [J]. BLOOD, 2012, 120 (21)
  • [3] Preclinical efficacy testing of Baxter's recombinant ADAMTS13 in a mouse model of TTP
    Schiviz, A.
    Lawo, J. P.
    Wuersch, K.
    Ehrlich, H.
    Scheiflinger, F.
    Schwarz, H-P
    Hoellriegl, W.
    Muchitsch, E-M
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 26 - 26
  • [4] Structural Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate
    Foettinger-Vacha, Alexandra
    Kaliwoda, Martin
    Matthiessen, Peter
    Hasslacher, Meinhard
    Rottensteiner, Hanspeter
    Turecek, Peter L.
    Mitterer, Artur
    Scheiflinger, Friedrich
    [J]. BLOOD, 2012, 120 (21)
  • [5] Functional Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.
    Rottensteiner, Hanspeter
    Plaimauer, Barbara
    Schrenk, Gerald
    Schmidt, Michaela
    Gruber, Bernadette
    Schreiner, Jutta
    Turecek, Peter L.
    Scheiflinger, Friedrich
    [J]. BLOOD, 2012, 120 (21)
  • [6] Preclinical Safety of Baxter's Recombinant Factor VIIa
    Dietrich, Barbara
    Kubik, Susan
    Auer, Wilfried
    Reipert, Birgit
    Horling, Frank
    Ehrlich, Hartmut J.
    Scheiflinger, Friedrich
    Schwarz, Hans Peter
    Muchitsch, Eva Maria
    [J]. BLOOD, 2010, 116 (21) : 608 - 608
  • [7] Normalization of ADAMTS13 activity in rats with an adjusted inhibitor titer by administration of recombinant ADAMTS13
    Schiviz, Alexandra
    Plaimauer, Barbara
    Kaufmann, Stefan
    Hoebarth, Gerald
    Wolfsegger, Martin
    Muchitsch, Eva-Maria
    Turecek, Peter L.
    Scheiflinger, Friedrich
    Rottensteiner, Hanspeter
    [J]. HAEMOPHILIA, 2014, 20 : 103 - 104
  • [8] The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction
    Austin, S. K.
    Starke, R. D.
    Lawrie, A. S.
    Cohen, H.
    Machin, S. J.
    Mackie, I. J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 536 - 544
  • [9] Preclinical safety pharmacology of Baxter's recombinant factor IX
    Dietrich, B.
    Kubik, S.
    Ehrlich, H.
    Scheiflinger, F.
    Schwarz, H. P.
    Muchitsch, E. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 118 - 118
  • [10] ADAMTS13 in nephrology [ADAMTS13 in der Nephrologie]
    Bockmeyer C.L.
    Modde F.
    Becker J.U.
    [J]. Der Nephrologe, 2013, 8 (1): : 69 - 70
12345